Emricasan (IDN-6556, PF-03491390) is a potent irreversible pan-caspase
inhibitor with the ability to rapidly reduce elevated levels of serum ALT,
AST and caspase mediated cleavage of cytokeratin-18 in HCV infected
1,2,3 To date, emricasan has been studied in more than 550
individuals and has exhibited a safety profile similar to placebo.
Emricasan is currently in three Phase 2 clinical trials, including two trials in
patients with liver cirrhosis. Here we report the effect of emricasan in
healthy volunteers on measures of serum caspase activity and apoptosis.
These results are compared with the effect of emricasan in subjects with
varying degrees of hepatic impairment, as well as the effect of emricasan
in subjects with severe renal impairment.